Molecular mechanisms of thalidomide and its derivatives

Key Points

Key points are not available for this paper at this time.

Abstract

binds many neosubstrates in the presence of various ligands. CRBN has been utilized in a novel protein knockdown technology named proteolysis targeting chimeras (PROTACs). Heterobifunctional molecules such as dBET1 are being developed to specifically degrade proteins of interest. Herein, we review recent advances in CRBN research.

Bookmark

View Full Paper

Cite This Study

Ito et al. (Wed,) studied this question.

synapsesocial.com/papers/6a01df2be8ec6bd19dcb0767 https://doi.org/https://doi.org/10.2183/pjab.96.016

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Animal models of human disease: zebrafish swim into view2007 · 2,182 citations
2Thalidomide in the treatment of lepra reactions1965 · 532 citations
3Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.1991 · 1,199 citations
4Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer proliferation and chemoresistance2016 · 195 citations
5Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome2018 · 515 citations

Bookmark

View Full Paper